In Brief
Refine Search
Biotechnology
Germany’s Evotec says it has taken notice of the statement made by Halozyme Therapeutics on November 22, stating that it has withdrawn its non-binding proposal to acquire Evotec for 11.00 euros per share in cash. 23 November 2024
Biotechnology
Colorado, USA-based OncoVerity announced the closing of a series A extension led by existing investors, argenX and RefinedScience. The value was not disclosed, but this extension follows a $30 million Series A fundraiser in March 2023. 22 November 2024
Biotechnology
Sweden-based BioArctic saw its fall 7.5% to 139.90 kronor on Friday, after its announced that its partner, Japan’s Eisa, has updated its revenue outlook for the Alzheimer’s treatment Leqembi (lecanemab) for the 2024 fiscal year (FY), which runs from April 2024 through March 2025. 11 November 2024
Biotechnology
Danish biotech Gubra announces that Germany’s Boehringer Ingelheim has decided to discontinue the development of the long-acting neuropeptide Y receptor type 2 (NPY2R) agonist BI 1820237 in obesity. 4 November 2024
Biotechnology
Japanese drugmaker Eisai has completed the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb (US brand name Leqembi) subcutaneous autoinjector for weekly maintenance dosing after it was granted Fast Track designation by the FDA. 1 November 2024
Pharmaceutical
GSK has announced its largest US manufacturing investment to date, dedicated to producing medicines and vaccines. 25 October 2024
Pharmaceutical
Following a re-examination, the European Medicines Agency’s human health committee, CHMP confirmed its initial recommendation to refuse the granting of a conditional marketing authorization for Masitinib AB Science’s masitinib. 18 October 2024
Pharmaceutical
University Medical Center Groningen (UMCG) and SHINE Europe have secured a 10.5 million euro ($11 million) grant to advance European production of terbium isotopes for cancer treatments. 17 October 2024
Pharmaceutical
Danish dermatology focused LEO Pharma has announced the launch of Anzupgo (delgocitinib) cream in Germany for the treatment of adult patients with moderate to severe chronic hand eczema (CHE), for whom topical corticosteroids are inadequate or inappropriate. 15 October 2024
Pharmaceutical
French pharma major Sanofi revealed it has entered into negotiations with private equity firm Clayton Dubilier & Rice (CD&R) for the potential sale of a 50% controlling stake in Opella, its consumer healthcare business. 14 October 2024
Pharmaceutical
The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
Biotechnology
Sirnaomics, a firm specializing in RNAi therapeutics, has entered into a subscription agreement with biotech specialist Poon Hung Fai. 4 October 2024
Biotechnology
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Biotechnology
Oxford, UK-based Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. 3 October 2024
Pharmaceutical
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
article
The European Medicines Agency’s (EMA) Committee for Human Medicinal Products (CHMP) has elected Bruno Sepodes as its new chair. 19 September 2024
Pharmaceutical
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Biotechnology
Zenas BioPharma announced the pricing of its upsized initial public offering of 13,235,294 shares of its common stock at an initial public offering price of $17.00 per share. 13 September 2024
Biotechnology
US pharma major Eli Lilly and Egyptian firm EVA Pharma have entered into an agreement to expand access to Olumiant (baricitinib) to an estimated 20,000 people in 49 low- to middle-income countries in Africa by 2030. 6 September 2024
Biotechnology
The European Commission has granted marketing authorization for yet another indication for Swiss pharma giant Roche’s cancer drug Tecentriq SC (atezolizumab; subcutaneous). 16 January 2024
Generics
Switzerland’s medicines regulator, Swissmedic, has updated its guidance regarding the authorization of generic medicines with certain active pharmaceutical ingredients (API). 16 January 2024
Pharmaceutical
The Indian government has urged the United States to enhance the frequency of inspections carried out by the US Food and Drug Administration (FDA) in India, aiming to boost pharmaceutical exports. 16 January 2024
Pharmaceutical
British pharma major AstraZeneca is to invest around $25 million in a new manufacturing facility in Taizhou, Zhejiang province. 16 January 2024
Biotechnology
In potentially the biggest pharma licensing deal ever, Japanese pharma major Daiichi Sankyo and US drug giant Merck & Co announced a collaboration in October. 16 January 2024
Biotechnology
Food and healthcare company Orion Group has made a bold step to expand its biotech interests, buying around a quarter of LegoChem Biosciences (Kosdaq: 141080) for $420 million. 16 January 2024
Pharmaceutical
German family-owned pharma major Boehringer Ingelheim has announced a further expansion and upgrade of its manufacturing plant in Koropi, Greece, where the pharmaceutical market is forecast to grow by 8.2%, from $7.5 billion in 2022 to $7.8 billion in 2023. 16 January 2024
Pharmaceutical
French healthcare non-profit Médecins Sans Frontières (MSF) has called on European lawmakers to amend a proposed law which would result in an effective export ban. 16 January 2024
Generics
Vyacheslav Kokeladze, a well-known Russian businessman and pharmaceutical tycoon, is investing about 1.4 billion roubles ($20 million) in the establishment of one of the country’s largest production facilities for generic medicines. 16 January 2024
Biotechnology
DISCO Pharmaceuticals, a specialist biotech unlocking the surfaceome of cancer cells at scale to identify new targets and develop first in class drugs, today emerges from stealth. 16 January 2024
Pharmaceutical
India’s Union budget is due to be published next month. 15 January 2024
Biotechnology
Arena BioWorks has announced its launch as a biomedical research institute with a mission to uncover mechanisms of disease by engaging in basic biological research that will be translated into lifesaving biotech therapeutics. 15 January 2024
Biotechnology
Belgian biotech BioSenic has reached agreement on a binding term sheet with privately-held Australian firm Phebra on the development of the first oral formulation of arsenic troxide for chronic graft versus host disease (cGvHD) treatment. 15 January 2024
Biosimilars
South Korea’s Celltrion has announced the next phase of its strategic transformation from a developer of the world's first monoclonal antibody (MAb) biosimilar to an innovative company focused on new drug development at the 42nd Annual JP Morgan Healthcare Conference in San Francisco, California. 15 January 2024
Biotechnology
Shanghai-headquartered JiXing Pharmaceuticals has announced the acquisition of US biotech major Biogen’s (Nasdaq: BIIB) BIIB131 for global clinical development. 15 January 2024
Pharmaceutical
Swiss specialty pharmaceutical company Santhera Pharmaceuticals has announced the launch of Agamree (vamorolone) in Germany. 15 January 2024
Biotechnology
Belgian biotech start-up ExeVir Bio today announced new data demonstrating that its antibodies are highly potent in neutralizing currently circulating COVID-19 Omicron variants. 15 January 2024
Pharmaceutical
Earlier this month US biotech major Amgen presented at the JP Morgan’s 42nd Annual Healthcare Conference, highlighting its pillars of business. 15 January 2024
Generics
Russia plans to revise the main concepts of public procurements of anti-tuberculosis drugs in a move to switch on the purchases of more efficient drugs with lower cost and side effects, The Pharma Letter’s local correspondent reports. 15 January 2024
Biotechnology
Massachusetts, USA-based Dyne Therapeutics has raised $345 million, shortly after announcing encouraging biomarker data for its Duchenne muscular dystrophy (DMD) candidate. 15 January 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze